Industry Wire 225

  1. Robert F. Kennedy Jr. looks to close “entire” FDA departments.
  2. Ambulance hits cyclist, then bills him $2k for ride to hospital.
  3. Physicians make up 16 of the 20 top-paying occupations.
  4. NH review supports making PAs’ scope of practice equal to NPs.
  5. Astrana acquires $745M in assets from LA-based Prospect Health.
  6. CDC: one in five adults experience anxiety or depression.
  7. Man gets 2 years in prison for accessing Justice Ginsburg’s EHR.
  8. Aetna and Optum settling ‘dummy code’ class-action lawsuit.
  9. Ex “Sesame Street” exec to lead St. Jude Children’s fundraising marketing.
  10. Medicare-focused payors stocks surge after Trump win.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]